Loading...
XBRU
FAGR
Market cap2.00bUSD
Jun 18, Last price  
23.75EUR
1D
-0.84%
1Q
9.70%
Jan 2017
144.52%
IPO
155.57%
Name

Fagron NV

Chart & Performance

D1W1MN
XBRU:FAGR chart
P/E
21.63
P/S
2.00
EPS
1.10
Div Yield, %
1.47%
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
10.28%
Revenues
872m
+14.28%
283,248,000276,971,000304,368,000354,506,000391,315,000424,056,000492,330,000547,020,000386,119,000447,056,000472,996,000421,839,000436,934,000471,679,000534,695,000555,971,000573,808,000683,881,000762,991,000871,960,000
Net income
81m
+14.18%
15,063,00012,123,00016,260,00014,900,00019,639,00022,479,00028,140,00043,906,000-32,102,00016,226,000-202,328,000-20,562,00046,658,00042,486,00055,687,00059,601,00061,004,00069,612,00070,547,00080,554,000
CFO
110m
+2.34%
34,541,00017,570,00027,100,00027,741,00039,496,00042,126,00072,147,00067,744,00063,078,000101,696,00073,311,00067,504,00084,247,00073,278,00077,175,00092,953,00078,419,000109,458,000107,379,000109,893,000
Dividend
May 19, 20250.35 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fagron N.V. is a specialized pharmaceutical compounding firm focused on delivering tailored medicinal solutions. The company caters to a diverse range of clients, including hospitals, pharmacies, clinics, and individual patients. Beyond providing direct services, Fagron N.V. actively drives innovation by developing cutting-edge concepts, delivery methods, and specific formulations for pharmaceutical compounding. Its extensive product line includes essential raw materials, specialized tools and equipment, semi-finished goods, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Furthermore, the company supports professional development through the Fagron Academy, offering comprehensive education and training programs for medical prescribers and pharmacists. With a significant global presence, Fagron N.V. operates across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company underwent a name change in January 2015, rebranding from its former identity, Arseus N.V., to Fagron N.V.
IPO date
Oct 05, 2007
Employees
3,035
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT